View Future GrowthHigh Tech Pharm 過去の業績過去 基準チェック /26High Tech Pharmは、平均年間46.9%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間12% 2.1%収益成長率で 減少しています。 High Tech Pharmの自己資本利益率は7%であり、純利益率は13.1%です。主要情報46.95%収益成長率46.03%EPS成長率Pharmaceuticals 業界の成長11.32%収益成長率-2.15%株主資本利益率7.01%ネット・マージン13.07%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.すべての更新を表示Recent updatesNew Risk • May 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.9b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.お知らせ • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea分析記事 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.分析記事 • Sep 02Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is LackingIt's not a stretch to say that High Tech Pharm Co., Ltd.'s ( KOSDAQ:106190 ) price-to-earnings (or "P/E") ratio of...Buy Or Sell Opportunity • Jul 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to ₩12,960. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jun 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to ₩12,970. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Jun 11We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.お知らせ • Feb 25High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 286, daegeum-ro, eumseong-gun, chungcheongbuk-do, chungju South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩66.67 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩142.8b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.分析記事 • Oct 23A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)Key Insights Using the 2 Stage Free Cash Flow to Equity, High Tech Pharm fair value estimate is ₩16,394 With ₩15,600...Buy Or Sell Opportunity • Sep 23Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to ₩13,030. The fair value is estimated to be ₩16,394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Aug 06Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 02Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩16,030, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 56% over the past three years.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩15,130, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.分析記事 • May 09There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price JumpHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩12,200, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.8% over the past three years.分析記事 • Apr 23Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • Dec 20Inaugural dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 1.1%.Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩16,440, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 20 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 0.8%.Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.分析記事 • Feb 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 19Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...Is New 90 Day High Low • Jan 14New 90-day high: ₩26,350The company is up 118% from its price of ₩12,100 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: ₩20,150The company is up 63% from its price of ₩12,400 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.分析記事 • Dec 15What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?The big shareholder groups in High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) have power over the company. Large companies...Is New 90 Day High Low • Dec 07New 90-day high: ₩15,200The company is up 27% from its price of ₩11,950 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.収支内訳High Tech Pharm の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A106190 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2669,0509,0245,60196631 Dec 2570,18311,4753,12281730 Sep 2575,60011,9803,743030 Jun 2574,65310,5643,691031 Mar 2573,57812,6273,835031 Dec 2477,51313,7103,790030 Sep 2481,55814,5583,281030 Jun 2483,50213,5223,120031 Mar 2482,54511,5962,714031 Dec 2376,7728,0762,601030 Sep 2379,1758,1141,993030 Jun 2394,1027,9312,315031 Mar 23102,1506,7992,568031 Dec 22102,9475,8732,705030 Sep 2288,68853,337030 Jun 2270,212-1,2053,109031 Mar 2267,869-2,9773,317031 Dec 2173,287-1,2253,310030 Sep 2179,120-1,0544,515030 Jun 2185,343-3674,977031 Mar 2179,496-2,5354,727031 Dec 2074,462-3,1524,551030 Sep 2072,142-5,6303,182030 Jun 2073,147-7,3402,647031 Mar 2067,977-4,7432,397031 Dec 1963,068-4,2182,330030 Sep 1961,495-9172,595030 Jun 1954,3811,1162,569031 Mar 1960,0132,4132,592-4531 Dec 1866,3882,6082,537030 Sep 1869,8532,7112,143030 Jun 1870,4302,8631,972-1631 Mar 1867,5932,6401,928131 Dec 1766,0502,1002,02910130 Sep 1765,5344,8662,26112030 Jun 1758,8473,5142,30313631 Mar 1754,0814,4492,10316431 Dec 1654,8365,2801,9911930 Sep 1650,6603,0241,8156030 Jun 1653,3735,4001,6645531 Mar 1653,4526,2631,7246631 Dec 1548,0926,5441,6648030 Sep 1547,6048,6131,8074530 Jun 1545,8449,0791,94650質の高い収益: A106190は 高品質の収益 を持っています。利益率の向上: A106190の現在の純利益率 (13.1%)は、昨年(17.2%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A106190過去 5 年間で収益を上げており、収益は年間46.9%増加しています。成長の加速: A106190は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: A106190は過去 1 年間で収益成長率がマイナス ( -28.5% ) となったため、 Pharmaceuticals業界平均 ( 25.5% ) と比較することが困難です。株主資本利益率高いROE: A106190の 自己資本利益率 ( 7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/27 17:47終値2026/06/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋High Tech Pharm Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
New Risk • May 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩148.9b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years.
お知らせ • Feb 24High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea
分析記事 • Feb 10High Tech Pharm Co., Ltd. (KOSDAQ:106190) Stock Rockets 36% But Many Are Still Ignoring The CompanyHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shareholders would be excited to see that the share price has had a great...
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.
分析記事 • Sep 02Investor Optimism Abounds High Tech Pharm Co., Ltd. (KOSDAQ:106190) But Growth Is LackingIt's not a stretch to say that High Tech Pharm Co., Ltd.'s ( KOSDAQ:106190 ) price-to-earnings (or "P/E") ratio of...
Buy Or Sell Opportunity • Jul 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to ₩12,960. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jun 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to ₩12,970. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Jun 11We Think High Tech Pharm (KOSDAQ:106190) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Apr 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
お知らせ • Feb 25High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 286, daegeum-ro, eumseong-gun, chungcheongbuk-do, chungju South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩66.67 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).
New Risk • Dec 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩142.8b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023)Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
分析記事 • Oct 23A Look At The Intrinsic Value Of High Tech Pharm Co., Ltd. (KOSDAQ:106190)Key Insights Using the 2 Stage Free Cash Flow to Equity, High Tech Pharm fair value estimate is ₩16,394 With ₩15,600...
Buy Or Sell Opportunity • Sep 23Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to ₩13,030. The fair value is estimated to be ₩16,394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Aug 06Is High Tech Pharm (KOSDAQ:106190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jul 02Subdued Growth No Barrier To High Tech Pharm Co., Ltd. (KOSDAQ:106190) With Shares Advancing 25%High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩16,030, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 56% over the past three years.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩15,130, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years.
分析記事 • May 09There's Reason For Concern Over High Tech Pharm Co., Ltd.'s (KOSDAQ:106190) Massive 25% Price JumpHigh Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) shares have continued their recent momentum with a 25% gain in the last...
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩12,200, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.8% over the past three years.
分析記事 • Apr 23Is High Tech Pharm (KOSDAQ:106190) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • Dec 20Inaugural dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 1.1%.
Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩16,440, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 20 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 0.8%.
Reported Earnings • Nov 05Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 18First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
分析記事 • Feb 23We Think High Tech Pharm (KOSDAQ:106190) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 19Did High Tech Pharm's (KOSDAQ:106190) Share Price Deserve to Gain 91%?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...
Is New 90 Day High Low • Jan 14New 90-day high: ₩26,350The company is up 118% from its price of ₩12,100 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: ₩20,150The company is up 63% from its price of ₩12,400 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
分析記事 • Dec 15What Is The Ownership Structure Like For High Tech Pharm Co., Ltd. (KOSDAQ:106190)?The big shareholder groups in High Tech Pharm Co., Ltd. ( KOSDAQ:106190 ) have power over the company. Large companies...
Is New 90 Day High Low • Dec 07New 90-day high: ₩15,200The company is up 27% from its price of ₩11,950 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS ₩89.00The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.